Costeff Syndrome (3-methylglutaconic aciduria type III) is a rare genetic condition causing early-onset optic atrophy along with movement difficulties such as chorea and spasticity later in life. Genetic testing and specialized metabolic/neuro-ophthalmology care for this condition are essentially unavailable within Ghana. Optic Atrophy Treatment Center works with Ghanan families exploring stem cell therapy for the optic nerve component of Costeff Syndrome.
As an extremely rare metabolic-genetic condition, Costeff Syndrome requires specialized diagnostic testing (urine organic acid analysis, genetic testing for the OPA3 gene) that is not available within Ghana. Families often travel abroad for both diagnostic confirmation and to explore treatment options for the optic nerve damage.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Stem cell therapy is studied for its potential to help support optic nerve tissue affected by Costeff Syndrome. It addresses the vision component only — the movement-related features (chorea, spasticity) require ongoing management by a neurologist.
Suitability depends on the stage and cause of the condition. Before travelling, our team reviews:

Stem Cell Cure India made me believe in the treatment right from the first consultation. The doctors went through the therapy in depth and the staff was always there to help. I was secure and respected during my procedure

Amazing experience at Stem Cell Cure India. Doctors were very considerate, the whole process was very well organized. Strongly recommend for anyone considering stem cell therapy
“No, our evaluation and treatment address the optic nerve/vision component only. Movement-related symptoms should be managed by a neurologist.”
” It’s helpful if available, but not mandatory — our team can review based on clinical history and OCT/visual field findings.”
“OCT scan, visual field test, any metabolic/genetic test results, and a summary of when vision loss and movement symptoms began.”

We would love to hear from you! Please fill out the form below.